John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.

Articles by John Carroll

Acadia surges after nabbing 'breakthrough' title for late-stage Parkinson's drug

The FDA has just added a fresh boost to Acadia Pharmaceuticals, naming its late-stage Parkinson's drug pimavanserin a "breakthrough" therapy deserving rapid regulatory response as it nears the finish line with a closely watched marketing application.

Novo Nordisk abandons anti-inflammatory R&D work, spotlights diabetes, obesity

Among all the pharma companies, Novo Nordisk always stood out for its relentless R&D focus on diabetes and obesity. Today, the Danish company amped up that concentration another notch, jettisoning a group of clinical programs and winding down its work in anti-inflammatory treatments. And the pharma player added that the move would hit some 400 staffers, with close to half likely to lose their jobs at Novo.

UPDATED: Cabozantinib flops against prostate cancer, forcing big job cuts at Exelixis

Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.

Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some high-profile attention for a batch of preliminary numbers suggesting a trend toward lower cardiovascular risks.

Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma giant painted in the numbers, completing the late-stage picture for a closely watched therapy that has the potential to rival the most successful drug franchises now on the market.

Band of West Coast biotech insiders pushes oral anticoagulant to PhIII

Some well-known biopharma execs on the West Coast, including Impax Labs founder and former CEO Larry Hsu, have teamed up on a low budget, late-stage program for an oral anticoagulant.

Booming Gilead blueprints an overhaul of its campus

After more than doubling its work force over the past 6 years, Gilead is investing part of the fortune it has reaped from HIV drugs as well as the hep C therapy Sovaldi in a complete makeover of its big campus in Foster City, CA.

Round two? Market rumors on a new Pfizer bid for AstraZeneca heat up

The story about a potential new takeover offer for AstraZeneca by Pfizer will not die.

Biotech upstart Dezima will take on Merck and Lilly in PhIII CETP showdown

In one of the most improbable rivalries in the drug development world, tiny Dutch biotech Dezima today laid claim to a successful Phase IIb study of its CETP cholesterol drug TA-8995, putting it on track to a 2015 launch for a Phase III showdown with two giants in the field, Eli Lilly and Merck.

China's new biotech billionaire beefs up cardio pipeline with $600M buyout

Newly minted biopharma billionaire Liu Dianbo has added to his fortune while burnishing his rep as one of the top biotech drug developers in China. His company, Luye Pharma Group, acquired a 58% stake in Beijing Jialin Pharma Pharmaceutical for close to $600 million, beefing up its pipeline of cardiovascular drugs while expanding its product lineup.